Synapse - Works

Results (5608)

Duration of the anti-androgen in men undergoing 6 months of an LHRH agonist and radiation therapy for unfavorable-risk prostate cancer and the risk of death

Meeting Abstract

Sanford, N. N.; Chen, M. H.; Loffredo, M.; Renshaw, A.; Kantoff, P. W.; D'Amico, A. V.
International Journal of Radiation Oncology, Biology, Physics (2016)

Fulltext@MSK | Save

Updated results from a phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: The CheckMate 016 study

Meeting Abstract

Hammers, H. J.; Plimack, E. R.; Infante, J. R.; Rini, B. I.; McDermott, D. F.; Lewis, L. D.; Voss, M. H.; Sharma, P.; Pal, S. K.; Razak, A.; more...
BJU International (2016)

Fulltext@MSK | Save

JAVELIN renal 101: A phase 3 study of avelumab in combination with axitinib vs sunitinib as first-line treatment for patients with advanced renal cell carcinoma (aRCC)

Meeting Abstract

Choueiri, T. K.; Rini, B. I.; Cosgriff, T.; Miyake, H.; Vogelzang, N. J.; Kannourakis, G.; Mariani, M.; Chiruzzi, C.; Albiges, L.; Haanen, J. B.; more...
BJU International (2016)

Fulltext@MSK | Save

RECORD-4 multicenter phase 2 trial of second-line everolimus (EVE) in patients with metastatic renal cell carcinoma (mRCC): Anti-VEGF cohort subanalysis

Meeting Abstract

Cosgriff, T.; Yang, L.; Alyasova, A.; Ye, D.; Karpenko, A.; Alekseev, B.; Kowalyszyn, R.; Karyakin, O.; Neron, Y.; Collins, L. T.; more...
BJU International (2016)

Fulltext@MSK | Save

Anti-tumor activity of PEGylated human IL-10 (AM0010) in renal cancer alone and in combination with anti-PD1

Meeting Abstract

Naing, A.; Pant, S.; Infante, J.; Papadopoulos, K.; Autio, K.; Wong, D.; Ott, P.; Falchook, G.; Patel, M.; Whiteside, M.; more...
BJU International (2016)

Fulltext@MSK | Save

Treatment variance between experts and community clinicians: Analysis of an online decision tool for renal cell carcinoma (RCC)

Meeting Abstract

Rosenthal, K.; Choueiri, T.; Motzer, R.; Ryan, C.; Obholz, K.; Hutson, T.; Rini, B.
BJU International (2016)

Fulltext@MSK | Save

RECORD-4 multicenter phase 2 trial of second-line everolimus (EVE) in patients with metastatic renal cell carcinoma (mRCC): Anti-VEGF cohort subanalysis

Meeting Abstract

Cosgriff, T.; Yang, L.; Alyasova, A.; Ye, D.; Karpenko, A.; Alekseev, B.; Kowalyszyn, R.; Karyakin, O.; Neron, Y.; Collins, L. T.; more...
BJU International (2016)

Fulltext@MSK | Save

Two-year efficacy and safety update from the phase III CheckMate 025 study of nivolumab versus everolimus in patients with advanced renal cell carcinoma (aRCC)

Meeting Abstract

Plimack, E. R.; Motzer, R. J.; Escudier, B.; Sharma, P.; McDermott, D. F.; George, S.; Hammers, H. J.; Carducci, M.; Tykodi, S. S.; Sosman, J. A.; more...
BJU International (2016)

Fulltext@MSK | Save

Differential overall survival results in RECORD-3 study based on three distinct clear cell metastatic renal cell carcinoma molecular subgroups classified by BAP1 and/or PBRM1 mutations

Meeting Abstract

Hsieh, J.; Chen, D.; Wang, P.; Chen, Y. B.; Mahtab, M.; Pate, P.; Bhanot, U.; Berger, M.; Cheng, E.; Knox, J.; more...
BJU International (2016)

Fulltext@MSK | Save

A randomized phase 2 trial of CRLX101 in combination with bevacizumab in patients with metastatic renal cell carcinoma (mRCC) versus standard of care (SOC)

Meeting Abstract

Voss, M.; Hutson, T. E.; Hussain, A.; Vaishampayan, U.; Vogelzang, N. J.; Crowell, T.; Li, J.; Downing, W.; Senderowicz, A.; Stone, E.
BJU International (2016)

Fulltext@MSK | Save